Literature DB >> 7600744

Is ACE inhibition with lisinopril helpful in diabetic neuropathy?

A Reja1, S Tesfaye, N D Harris, J D Ward.   

Abstract

Thirteen diabetic patients with hypertension (mean diastolic blood pressure 96.2 +/- 1.1 mmHg) were included in a study to assess the effects of lisinopril (20 mg day-1) on measures of nerve function. Patients had nerve conduction velocity (NCV), temperature discrimination threshold (TDT), and vibration perception threshold (VPT) measurements. At the end of 12 weeks of treatment with lisinopril, there was a significant improvement in median motor NCV (mean change +/- SEM 2.7 +/- 0.6 m s-1, p < 0.0001), median sensory NCV (2.1 +/- 0.9 m s-1, p = 0.03), peroneal motor NCV (1.0 +/- 0.4 m s-1, p = 0.03), and sural sensory NCV (1.9 +/- 0.7 m s-1, p = 0.01) values. There were also significant improvements in warm TDT and VPT. Diastolic BP decreased significantly, but there was no significant change in HbA1. Double blind controlled studies are now needed to confirm the effect of lisinopril on measures of nerve function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600744     DOI: 10.1111/j.1464-5491.1995.tb00482.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  19 in total

1.  Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.

Authors:  Eric P Davidson; Lawrence J Coppey; Amey Holmes; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2011-07-28       Impact factor: 4.432

2.  Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.

Authors:  Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2010-10-30       Impact factor: 4.432

3.  Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis).

Authors:  S Tesfaye; R Malik; N Harris; J J Jakubowski; C Mody; I G Rennie; J D Ward
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

Review 4.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  Comparison of the effects of ascorbyl gamma-linolenic acid and gamma-linolenic acid in the correction of neurovascular deficits in diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

6.  Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy.

Authors:  Mitra Tavakoli; Omar Asghar; Uazman Alam; Ioannis N Petropoulos; Hassan Fadavi; Rayaz A Malik
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

Review 7.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.

Authors:  Gordon Sloan; Dinesh Selvarajah; Solomon Tesfaye
Journal:  Nat Rev Endocrinol       Date:  2021-05-28       Impact factor: 43.330

Review 8.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 9.  Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.

Authors:  Irina G Obrosova
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 10.  The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.

Authors:  Toomas Podar; Jaakko Tuomilehto
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.